Home » Stocks » GH

Guardant Health, Inc. (GH)

Stock Price: $106.72 USD -2.96 (-2.70%)
Updated Oct 30, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 10.63B
Revenue (ttm) 257.59M
Net Income (ttm) -120.37M
Shares Out 99.62M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $106.72
Previous Close $109.68
Change ($) -2.96
Change (%) -2.70%
Day's Open 108.98
Day's Range 105.30 - 109.60
Day's Volume 569,025
52-Week Range 55.90 - 114.33

More Stats

Market Cap 10.63B
Enterprise Value 9.73B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 99.62M
Float 85.46M
EPS (basic) -1.28
EPS (diluted) -1.27
FCF / Share -1.04
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.35M
Short Ratio 1.70
Short % of Float 2.75%
Beta 0.50
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 41.27
PB Ratio 9.88
Revenue 257.59M
Operating Income -132.97M
Net Income -120.37M
Free Cash Flow -100.21M
Net Cash 896.71M
Net Cash / Share 9.00
Gross Margin 55.77%
Operating Margin -51.62%
Profit Margin -46.70%
FCF Margin -38.90%
ROA -7.47%
ROE -11.52%
ROIC -14.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (10)

Buy 10
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$116.78*
(9.43% upside)
Low
100
Current: $106.72
High
130
Target: 116.78
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue21490.6449.8425.25
Revenue Growth136.52%81.85%97.4%-
Gross Profit14447.4318.223.13
Operating Income-82.37-92.94-76.61-43.85
Net Income-75.65-85.06-83.22-46.14
Shares Outstanding90.6030.4012.5813.05
Earnings Per Share-0.84-2.80-7.07-3.53
Operating Cash Flow-47.13-72.19-72.24-36.71
Capital Expenditures-21.22-20.20-6.68-1.77
Free Cash Flow-68.35-92.39-78.92-38.48
Cash & Equivalents52341922195.26
Total Debt33.26-0.6617.04
Net Cash / Debt49041922178.22
Assets963587343117
Liabilities11562.4534.3336.87
Book Value79848330979.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Guardant Health, Inc.
Country United States
Employees 622
CEO Helmy Eltoukhy

Stock Information

Ticker Symbol GH
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: GH
IPO Date October 4, 2018

Description

Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.